Principles of lysosomal membrane digestion: Stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids

Annual Review of Cell and Developmental Biology

Volumn 21, Issue , 2005, Pages 81-103

  Kolter, Thomas ^a   Sandhoff, Konrad ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Glycosphingolipids; GM2 activator; Lysosomes; Saposins; Sphingolipids

Indexed keywords

ANIONIC LYSOSOMAL LIPID; BIS(MONOACYLGLYCERO)PHOSPHATE; CD1 ANTIGEN; CERAMIDE; CHOLESTEROL; GALACTOSYLCERAMIDE; GANGLIOSIDE GM2; GLYCOSPHINGOLIPID; HYDROLASE; LIPID; LIPID ANTIGEN; LIPID BINDING PROTEIN; LIPID TRANSFER PROTEIN; LYSOPHOSPHATIDIC ACID; PROSAPOSIN; PROTEIN SAP A; PROTEIN SAP B; PROTEIN SAP C; PROTEIN SAP D; SPHINGOLIPID; SPHINGOLIPID ACTIVATOR PROTEIN; SPHINGOLIPID ACTIVATOR PROTEIN 2; SPHINGOMYELIN; UNCLASSIFIED DRUG;

CELL SURFACE; ENDOCYTOSIS; ENZYME MECHANISM; HYDROPHILICITY; LIPIDOSIS; LYSOSOME MEMBRANE; MEMBRANE STRUCTURE; MEMBRANE TRANSPORT; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; SOLUBILITY;

ANIMALS; ANIONS; HUMANS; INTRACELLULAR MEMBRANES; LYSOSOMES; MEMBRANE LIPIDS; MODELS, BIOLOGICAL; SPHINGOLIPID ACTIVATOR PROTEINS; SPHINGOLIPIDS;

EUKARYOTA;

EID: 25444443570     PISSN: 10810706     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.cellbio.21.122303.120013     Document Type: Review

References (121)

1. Ahn VE, Faull KF, Whitelegge JP, Fluharty AL, Prive GG. 2003. Crystal structure of saposin B reveals a dimeric shell for lipid binding. Proc. Natl. Acad. Sci. USA 100:38-43
2. Amidon B, Brown A, Waite M. 1996. Transacylase and phospholipases in the synthesis of bis(monoacylglycero)phosphate. Biochemistry 35:13995-4002
3. Anǵnieux C, Fraisier V, Maître B, Racine V, van der Wel N, et al. 2005. The cellular pathway of CD1c in immature and maturing dendritic cells. Traffic 6:286-302
4. Berent SL, Radin NS. 1981. Mechanism of activation of glucocerebrosidase by co-β-glucosidase (glucosidase activator protein). Biochim. Biophys. Acta 664:572-82
5. Bernardo K, Hurwitz R, Zenk T, Desnick RJ, Ferlinz K, et al. 1995. Purification, characterization, and biosynthesis of human acid ceramidase. J. Biol. Chem. 70:11098-102
6. Bradova V, Smid F, Ulrich-Bott B, Roggendorf W, Paton BC, Harzer K. 1993. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum. Genet. 92:143-52
7. Brotherus J, Renkonen O, Herrmann J, Fischer W, Herrmann, J. 1974. Novel stereoconfiguration in lyso-bis-phosphatidic acid of cultured BHK-cells. Chem. Phys. Lipids 13:178-82
8. Brown DA, London E. 2000. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275:17221-24
9. Burkhardt JK, Hüttler S, Klein A, Möbius W, Habermann A, et al. 1997. Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor. Eur. J. Cell Biol. 73:10-18
10. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, et al. 1997. Niemann-Pickl disease gene: homology to mediators of cholesterol homeostasis. Science 277:228-31
11. Chojnacki T, Dallner, G. 1988. The biological role of dolichol. Biochem. J. 251:1-9
12. Christomanou H, Aignesberger A, Linke RP. 1986. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol. Chem. Hoppe-Seyler 367:879-90
13. Ciaffoni F, Salvioli R, Tatti M, Arancia G, Crateri P, Vaccaro AM. 2001. Saposin D solubilizes anionic phospholipid-containing membranes. J. Biol. Chem. 276:31583-89
14. Coe NR, Bernlohr DA. 1998. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta 1391:287-306
15. Conzelmann E, Burg J, Stephan G, Sandhoff K. 1982. Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2. Eur. J. Biochem. 123:455-64
16. Conzelmann E, Sandhoff K. 1978. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc. Natl. Acad. Sci. USA 75:3979-83
17. Conzelmann E, Sandhoff K. 1979. Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. Hoppe Seylers Z. Physiol. Chem. 360:1837-49
18. Davies JP, Chen FW, Ioannou YA. 2000. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 290:2295-98
19. de Alba E, Weiler S, Tjandra, N. 2003. Solution structure of human saposin C: pH-dependent interaction with phospholipid vesicles. Biochemistry 42:14729-40
20. Eskelinen E-L, Tanaka Y, Saftig P. 2003. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 13:137-45
21. Fabbro D, Grabowski GA. 1991. Human acid β-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites. J. Biol. Chem. 266:15021-27
22. Fischer G, Jatzkewitz H. 1977. The activator of cerebroside sulphatase. Binding studies with enzyme and substrate demonstrating the detergent function of the activator protein. Biochim. Biophys. Acta 481:561-72
23. Friedland N, Liou HL, Lobel P, Stock AM. 2003. Structure of a cholesterol-binding protein deficient in Niemann-Pick type C2 disease. Proc. Natl. Acad. Sci. USA 100:2512-17
24. Fürst W, Machleidt W, Sandhoff K. 1988. The precursor of sulfatide activator protein is processed to three different proteins. Biol. Chem. Hoppe Seyler 369:317-28
25. Fürst W, Sandhoff K. 1992. Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta 1126:1-16
26. Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, et al. 1996. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 5: 711-25
27. Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, et al. 2002. Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains. Nat. Immunol. 3:721-26
28. Giehl A, Lemm T, Bartelsen O, Sandhoff K, Blume A. 1999. Interaction of the GM2-activator protein with phospholipid-ganglioside bilayer membranes and with monolayers at the air-water interface. Eur. J. Biochem. 261:650-58
29. Goni FM, Alonso A. 2002. Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 531:38-46
30. Gutsmann T, Riekens B, Bruhn H, Wiese A, Seydel U, Leippe M. 2003. Interaction of amoebapores and NK-lysin with symmetric phospholipid and asymmetric lipopolysaccharide/phospholipid bilayers. Biochemistry 42:9804-12
31. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, et al. 2003. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426:803-9
32. Harzer K, Paton BC, Poulos A. 1989. Sphingolipid activator protein (SAP) deficiency in a 16-week old atypical Gaucher disease patient and his fetal sibling; biochemical signs of combined sphingolipidosis. Eur. J. Pediatr. 149:31-39
33. Hecht O, Van Nuland NA, Schleinkofer K, Dingley AJ, Bruhn H, et al. 2004. Solution structure of the pore forming protein of entamoeba histolytic. J. Biol. Chem. 279:17834-41
34. Heerklotz H. 2002. Triton promotes domain formation in lipid raft mixtures. Biophys. J. 83:2693-701
35. Heerklotz H, Szadkowska H, Anderson T, Seelig J. 2003. The sensitivity of lipid domains to small perturbations demonstrated by the effect of Triton. J. Mol. Biol. 329:793-99
36. Henning R, Stoffel W. 1973. Glycosphingolipids in lysosomal membranes. Hoppe-Seyler's Z. Physiol. Chem. 354:760-70
37. Hepbildikler ST, Sandhoff R, Kölzer M, Proia RL, Sandhoff K. 2002. Physiological substrates for human lysosomal β-hexosaminidase S. J. Biol. Chem. 277:2562-72
38. Hiesberger T, Hüttler S, Rohlmann A, Schneider W, Sandhoff K, Herz J. 1998. Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP). EMBO J. 17:4617-25
39. Ho MW, O'Brien JS. 1971. Gaucher's disease: deficiency of 'acid' β-glucosidase and reconstitution of enzyme activity in vitro. Proc. Natl. Acad. Sci. USA 68:2810-13
40. Hopkins CR, Gibson A, Shipman M, Miller K. 1990. Movement of internalized ligand-receptor complexes along a continuous endosomal reticulum. Nature 346:335-39
41. Kang SJ, Cresswell P. 2004. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nature Immunol. 5:175-81
42. Katzmann DJ, Babst M, Emr SD. 2001. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 106:145-55
43. Klein A, Henseler M, Klein C, Suzuki K, Harzer K, Sandhoff K. 1994. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. Biochem. Biophys. Res. Commun. 200:1440-48
44. Kobayashi T, Beuchat M-H, Lindsay M, Frias S, Palmiter RD. 1999. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nature Cell Biol. 1:113-18
45. Kobayashi T, Stang E, Fang KS, de Moerloose P, Parton RG, Gruenberg J. 1998. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature 392:193-97
46. Kolter T, Proia RL, Sandhoff K. 2002. Minireview: combinatorial ganglioside biosynthesis. J. Biol. Chem. 277:25859-62
47. Kolter T, Sandhoff K. 1998. Recent advances in the biochemistry of sphingolipidoses. Brain Pathol. 8:79-100
48. Kolter T, Sandhoff K. 1999. Sphingolipids-their metabolic pathways and the pathobiochemistry of neurodegenerative diseases. Angew. Chem. Int. Ed. 38:1532-68
49. Kretz KA, Carson GS, Morimoto S, Kishimoto Y, Fluharty AL, O'Brien JS. 1990. Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc. Natl. Acad. Sci. USA 87:2541-44
50. Lefrancois S, Zeng J, Hassan AJ, Canuel M, Morales CR. 2003. The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin. EMBO J. 22:6430-37
51. Li SC, Kihara H, Serizawa S, Li YT, Fluharty AL, Mayes JS, Shapiro LJ. 1985. Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide. J. Biol. Chem. 260:1867-71
52. Li SC, Sonnino S, Tettamanti G, Li YT. 1988. Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. J. Biol. Chem. 263:6588-91
53. Liepinsh E, Andersson M, Ruysschaert JM, Otting G. 1997. Saposin fold revealed by the NMR structure of NK-lysin. Nat. Struct. Biol. 4:793-95
54. Linke T, Wilkening G, Lansmann S, Moczall H, Bartelsen O, et al. 2001a. Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol. Chem. 382:283-90
55. Linke T, Wilkening G, Sadeghlar F, Mozcall H, Bernardo K, et al. 2001b. Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J. Biol. Chem. 276:5760-68
56. Liu Y, Wu Y-P, Wada R, Neufeld EB, Mullin KA, et al. 2000. Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse. Hum. Mol. Genet. 9:1087-92
57. London M, London E. 2004. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J. Biol. Chem. 279:9997-10004
58. Maggio B, Fanani ML, Oliveira RG. 2002. Biochemical and structural information transduction at the mesoscopic level in biointerfaces containing sphingolipids. Neurochem. Res. 27:547-57
59. Maier T, Strater N, Schuette CG, Klingenstein R, Sandhoff K, Saenger W. 2003. The X-ray crystal structure of human β-hexosaminidase B provides new insights into Sandhoff disease. J. Mol. Biol. 328:669-81
60. Malinina L, Malakhova ML, Teplov A, Brown RE, Patel DJ. 2004. Structural basis for glycosphingolipid transfer specificity. Nature 430:1048-53
61. Mark BL, Mahuran DJ, Cherney MM, Zhao D, Knapp S, James MN. 2003. Crystal structure of human β-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J. Mol. Biol. 327:1093-109
62. Marsh D. 1996. Lateral pressure in membranes. Biochim. Biophys. Acta 1286:183-223
63. Massey JB. 2001. Interaction of ceramides with phosphatidylcholine, sphingomyelin and sphingomyelin/cholesterol bilayers. Biochim. Biophys. Acta 1510:167-84
64. Matsuda J, Vanier MT, Saito Y, Tohyama J, Suzuki K. 2001. A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum. Mol. Genet. 10:1191-99
65. Matsuda J, Kido M, Tadano-Aritomi K, Ishizuka I, Tominaga K, et al. 2004. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse. Hum. Mol. Genet. 13:2709-23
66. Matsuzawa Y, Hostetler KY. 1979. Degradation of bis(monoacylglycero) phosphate by an acid phosphodiesterase in rat liver lysosomes. J. Biol. Chem. 254:5997-6001
67. Maxfield FR, McGraw TE. 2004. Endocytic recycling. Nat. Rev. Mol. Cell Biol. 5:121-32
68. Mehl E, Jatzkewitz H. 1964. A cerebrosidesulfatase from swine kidney. Hoppe Seylers Z. Physiol. Chem. 339:260-76
69. Merrill AH Jr. 2002. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem. 277:25843-46
70. Millat G, Marcais C, Rafi MA, Yamamoto T, Morris JA, et al. 1999. Niemann-Pick C1 disease: the 1106 IT substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. Am. J. Hum. Genet. 65:1321-29
71. Millat G, Chikh K, Naureckiene S, Sleat DE, Fensom AH, et al. 2001. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am. J. Hum. Genet. 69:1013-21
72. Möbius W, Herzog V, Sandhoff K, Schwarzmann G. 1999a. Intracellular distribution of a biotin-labeled ganglioside GM1 by immunoelectron microscopy after endocytosis in fibroblasts. J. Histochem. Cytochem. 47:1005-14
73. Möbius W, Herzog V, Sandhoff K, Schwarzmann G. 1999b. Gangliosides are transported from the plasma membrane to intralysosomal membranes as revealed by immuno-electron microscopy. Biosci. Rep. 19:307-16
74. Möbius W, van Donselaar E, Ohno-Iwashita Y, Shimada Y, Heijnen HF, et al. 2003. Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway. Traffic 4:222-31
75. Morimoto S, Martin BM, Kishimoto Y, O'Brien JS. 1988. Saposin D: a sphingomyelinase activator. Biochem. Biophys. Res. Commun. 156:403-10
76. Munford RS, Sheppard PO, O'Hara PJ. 1995. Saposin-like proteins (SAPLIP) carry out diverse functions on a common backbone structure. J. Lipid. Res. 36:1653-63
77. Munro S. 2003. Lipid rafts: elusive or illusive? Cell 115:377-88
78. Nakano T, Sandhoff K, Stumper J, Christomanou H, Suzuki K. 1989. Structure of full-length cDNA coding for sulfatide activator, a Co-β-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J. Biochem. 105:152-54
79. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, et al. 2000. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290:2298-301
80. O'Brien JS, Kretz KA, Dewji N, Wenger DA, Esch F, Fluharty AL. 1988. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science 241: 1098-1101
81. Okamura N, Kiuchi S, Tamba M, Kashima T, Hiramoto S, et al. 1999. A porcine homolog of the major secretory protein of human epididymis, HE1, specifically binds cholesterol. Biochim. Biophys. Acta 1438:377-87
82. Opekarová M, Tanner W. 2003. Specific lipid requirement of membrane proteins-a putative bottleneck in heterologous expression. Biochim. Biophys. Acta 1610:11-22
83. Osiecki-Newman K, Legler G, Grace M, Dinur T, Gatt S, et al. 1988. Human acid β-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites. Enzyme 40:173-88
84. Patterson MC. 2003. A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C. Neurology 9:301-10
85. Patterson MC, Vanier MT, Suzuki K, Morris JA, Carstea E, et al. 2001. Niemann-Pick disease type C: a lipid trafficking disorder. In The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, III:3611-33. New York: McGraw-Hill. 8th ed.
86. Pentchev PG, Boothe AD, Kruth HS, Weintroub H, Stivers J, Brady RO. 1984. A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J. Biol. Chem. 259:5784-91
87. Pentchev PG, Comly ME, Kruth HS, Patel S, Proestel M, Weintroub H. 1986. The cholesterol storage disorder of the mutant BALB/c mouse. J. Biol. Chem. 261:2772-77
88. Platt FM, Walkley SU. 2004. Lysosomal defects and storage. In Lysosomal Disorders of the Brain, ed. FM Platt, SU Walkley, pp. 32-49. New York: Oxford Univ. Press
89. Salvioli R, Tatti M, Ciaffoni F, Vaccaro AM. 2000. Further studies on the reconstitution of glucosylceramidase activity by Sap C and anionic phospholipids. FEBS Lett. 472:17-21
90. Sandhoff K, Kolter T, Harzer K. 2001. Sphingolipid activator proteins. In The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, III:3371-88. New York: McGraw-Hill. 8th ed.
91. Sandhoff K, Kolter T. 1996. Topology of glycosphingolipid degradation. Trends Cell Biol. 6:98-103
92. Sarmientos F, Schwarzmann G, Sandhoff K. 1986. Specificity of human glucosylceramide β-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system. Eur. J. Biochem. 160:527-35
93. Schnabel D, Schröder M, Fürst W, Klein A, Hurwitz R, et al. 1992. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J. Biol. Chem. 267:3312-15
94. Schnabel D, Schröder M, Sandhoff K. 1991. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett. 284:57-59
95. Simons K, Ikonen E. 1997. Functional rafts in cell membranes. Nature 387:569-72
96. Spiegel R, Bach G, Sury V, Mengistu G, Meidan B, et al. 2005. A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. Mol. Genet. Metab. 84:160-66
97. Sun Y, Qi X, Grabowski GA. 2003. Saposin C is required for normal resistance of acid β-glucosidase to proteolytic degradation. J. Biol. Chem. 278:31918-23
98. Suzuki K. 1994. Genetic disorders of lipid, glycoprotein, and mucopolysaccharide metabolism. In Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, ed. GJ Siegel, BW Agranoff, RW Albers, PB Molinoff, pp. 793-812. New York: Raven. 5th ed.
99. Suzuki K, Chen GC. 1968. GM1-gangliosidosis (generalized gangliosidosis). Morphology and chemical pathology. Pathol. Eur. 3:389-408
100. Suzuki K, Vanier MT. 1999. Lysosomal and peroxisomal diseases. In Basic Neurochemistry-Molecular, Cellular and Medical Aspects, ed. GJ Siegel, BW Agranoff, RW Albers, SK Fisher, MD Uhler, pp. 821-39. Philadelphia: Lippincott-Raven. 6th ed.
101. Tettamanti G. 2004. Ganglioside/glycosphingolipid turnover: new concepts. Glycoconjugate J. 20:301-17
102. Umebayashi K. 2003. The roles of ubiquitin and lipids in protein sorting along the endocytic pathway. Cell. Struct. Funct. 28:443-53
103. Vaccaro AM, Ciaffoni F, Tatti M, Salvioli R, Barca A, et al. 1995. pH-dependent conformational properties of saposins and their interactions with phospholipid membranes. J. Biol. Chem. 270:30576-80
104. van der Goot FG, Gruenberg J. 2002. Oiling the wheels of the endocytic pathway. Trends Cell Biol. 12:296-99
105. van Meer G, Lisman Q. 2002. Sphingolipid transport: rafts and translocators. J. Biol. Chem. 277:25855-58
106. van Weely S, Brandsma M, Strijland A, Tager JM, Aerts JM. 1993. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1181:55-62
107. Vogel A, Schwarzmann G, Sandhoff K. 1991. Glycosphingolipid specificity of the human sulfatide activator protein. Eur. J. Biochem. 200:591-97
108. vonCoburg A. 2003. Untersuchung der Lipidnachbarschaft von derivatisienem GM1 in Modellmembranen und kultivierten Zellen. PhD thesis. Universität Bonn. 169 pp.
109. Wendeler M, Hoernschemeyer J, Hoffmann D, Kolter T, Schwarzmann G, Sandhoff K. 2004. Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation. Eur. J. Biochem. 271:614-27
110. Werth N, Schuette CG, Wilkening G, Lemm T, Sandhoff K. 2001. Degradation of membrane-bound ganglioside GM2 by β-hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids. J. Biol. Chem. 276:12685-90
111. Wilkening G, Linke T, Sandhoff K. 1998. Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. J. Biol. Chem. 273:30271-78
112. Wilkening G, Linke T, Uhlhorn-Dierks G, Sandhoff K. 2000. Degradation of membrane-bound Ganglioside GM1. J. Biol. Chem. 275:35814-19
113. Winau F, Schwierzeck V, Hurwitz R, Remmel N, Sieling PA, et al. 2004. Saposin C is required for lipid presentation by human CD1b. Nat. Immunol. 5:169-74
114. Winchester BG. 2004. Primary defects in lysosomal enzymes. In Lysosomal Disorders of the Brain, ed. FM Platt, SU Walkley, pp. 81-130. New York: Oxford Univ. Press
115. Wright CS, Li SC, Rastinejad F. 2000. Crystal structure of human GM2-activator protein with a novel β-cup topology. J. Mol. Biol. 304:411-22
116. Wright CS, Zhao Q, Rastinejad F. 2003. Structural analysis of lipid complexes of GM2-activator protein. J. Mol. Biol. 331:951-64
117. Xu X, Bittman R, Duportail G, Heissler D, Vilcheze C, London E. 2001. Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant, fungal, and disease-associated sterols and comparison of sphingomyelin, cerebrosides, and ceramide. J. Biol. Chem. 276:33540-46
118. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, et al. 2003. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA 100:3445-49
119. Zajonc DM, Elsliger MA, Teyton L, Wilson IA. 2003. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 Å. Nat. Immunol. 4:808-15
120. Zervas M, Dobrenis K, Walkley SU. 2001. Neurons in Niemann-Pick disease Type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol. 60:49-64
121. Zhou D, Cantu C 3rd, Sagiv Y, Schrantz N, Kulkarni AB, et al. 2004. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303:523-27